---
schema_version: "secwatch.filing_event.v1"
accession: "0001688757-24-000088"
form_type: "8-K"
ticker: "ESTA"
cik: "0001688757"
company_name: "ESTABLISHMENT LABS HOLDINGS INC."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:38:29.030767+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Establishment Labs Q3 revenue $40.2M, cuts 2024 guidance to $165-168M, raises $50M in direct offering

## Summary
- Q3 revenue $40.2M vs $38.5M YoY; net loss $16.7M vs $29.3M loss YoY; adjusted EBITDA loss $7.0M vs $16.3M loss.
- 2024 revenue guidance reduced to $165-168M from prior $174-184M due to FDA delay and Brazil weakness.
- Cash $39.7M at Sep 30; pro forma $114M after $25M Oaktree draw and $50M registered direct offering (5% discount).
- FDA approved Motiva Implants Sep 26; U.S. launch added 250+ accounts in first three weeks; expects >$35M U.S. revenue in 2025.
- Oaktree facility amended: $25M Tranche D available through Dec 31, 2025 subject to revenue milestones.

## SEC filing metadata
- accession: 0001688757-24-000088
- form_type: 8-K
- ticker: ESTA
- cik: 0001688757
- company_name: ESTABLISHMENT LABS HOLDINGS INC.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1688757/000168875724000088/0001688757-24-000088-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1688757/000168875724000088/esta-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001688757-24-000088
- JSON: https://secwatch.observer/filing/0001688757-24-000088.json
- Plain text: https://secwatch.observer/filing/0001688757-24-000088.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.